Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 28.7 USD -1.07% Market Closed
Market Cap: 2.4B USD
Have any thoughts about
Beam Therapeutics Inc?
Write Note

Beam Therapeutics Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beam Therapeutics Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Beam Therapeutics Inc
NASDAQ:BEAM
Total Liabilities
$478.4m
CAGR 3-Years
32%
CAGR 5-Years
71%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

Beam Therapeutics Inc
Glance View

Market Cap
2.4B USD
Industry
Biotechnology

Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.

BEAM Intrinsic Value
9.68 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Beam Therapeutics Inc's Total Liabilities?
Total Liabilities
478.4m USD

Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Total Liabilities amounts to 478.4m USD.

What is Beam Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
71%

Over the last year, the Total Liabilities growth was -21%. The average annual Total Liabilities growth rates for Beam Therapeutics Inc have been 32% over the past three years , 71% over the past five years .

Back to Top